drug interactions with glp-1 mechanism of action of analogues, DPP-IV inhibitors, and Interaction between drugs and GLP-1

Treatment was stopped, and the patient was permanently withdrawn from the study

At week 52, mean HbA1c was 5.8% (40 mmol/mol) for 5 mg, 5.6% (38 mmol/mol) for 10 mg, and 5.4% (35 mmol/mol) for 15 mg of tirzepatide compared with 6.9% (52 mmol/mol) for dulaglutide [9]

Serretti A, Mandelli L

The first GLP-1 analogue to be developed was liraglutide (Fig

These side effects are typically mild to moderate in severity and tend to improve over time

However, the incidence of other common adverse events, such as urinary tract infections, drug discontinuation due to adverse events, severe hypoglycemia, and severe adverse events, did not differ significantly between combination therapy and monotherapies (Fig